Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 42.78B |
| Revenue (ttm) | 1.78B |
| Net Income (ttm) | 330.18M |
| Shares Out | 446.90M |
| EPS (ttm) | 0.81 |
| PE Ratio | 63.49 |
| Forward PE | 60.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,663,500 |
| Average Volume | 1,666,832 |
| Open | 60.00 |
| Previous Close | 58.85 |
| Day's Range | 51.20 - 64.50 |
| 52-Week Range | 11.54 - 70.15 |
| Beta | 0.21 |
| RSI | 41.49 |
| Earnings Date | Apr 27, 2026 |
About HKG:2315
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally. It operates through five segments: Gene-Editing; Pharmacological Efficacy; Model Animals; Antibody Development; and Other. The company provides the customized gene editing services based on animals and cells to meet the needs of basic science research and drug development of the customers; provid... [Read more]
Financial Performance
In 2025, HKG:2315's revenue was 1.38 billion, an increase of 40.63% compared to the previous year's 980.45 million. Earnings were 173.20 million, an increase of 416.37%.
Financial numbers in CNY Financial StatementsNews
Strengthening Translational Research in India: GVSAP and Biocytogen Expand Collaboration
Business Wire India GV Safety Assessment Platform (GVSAP), an integrated preclinical R&D enabler within the GVRP portfolio, today announced an...
Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions
BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovativ...
Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website
Business Wire India Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with...
Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development
BEIJING — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovativ...
Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing
BEIJING — In response to Harbour BioMed’s recent press release regarding a procedural development in their ongoing legal claim, Biocytogen issues the following statement: Biocytogen stands by its core...
Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform
Beijing, China: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315) today announced that the key technology of its independently developed RenMab™fully human antibody mouse platfo...
Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
BEIJING & NANJING, China — Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly ...
Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors
Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs) Biocytogen’s RenLite® meets Acepodia’s AD2C for precision oncology solutions BEIJING & ALAMEDA, Calif....